Global Atrophic Vaginitis Treatment Market Size by Treatment Type, Drug Class, Dosage Form and Patient Type

8.29%
CAGR (2026-2034)
3.14 USD Bn.
Forecast Market Size
315
Report Pages
163
Market Tables

Overview

Global Atrophic Vaginitis Treatment Market size was valued at USD 3.14 Billion in 2025, and the total revenue is expected to grow at a CAGR of 8.29% from 2026 to 2034, reaching nearly 6.43 billion by 2034.

Atrophic Vaginitis Treatment Market Overview

The Global Atrophic Vaginitis Treatment Market includes hormonal and non-hormonal therapies for vaginal atrophy, primarily affecting postmenopausal women. Atrophic vaginitis treatment market selective estrogen receptor modulators (SERMs), includes estrogen-based therapies, vaginal DHEA (prasterone), vaginal moisturizers, lubricants, and other emerging treatment options. Rising availability of different formulations and treatment approaches is growing therapeutic choices for patients.

North America and Europe remain significant markets due to relatively high awareness and treatment penetration, whereas APAC presents significant growth potential as healthcare access and awareness of menopausal health continue to improve.

Atrophic Vaginitis Treatment Market Size and Share Analysis

Atrophic Vaginitis Treatment Market Growth
To know about the Research Methodology :- Request Free Sample Report

Atrophic Vaginitis Treatment Market Key Highlights 2025-2034:

Market Parameter Value / Insight Trend
Global Atrophic Vaginitis Treatment Market Size (2025) USD 3.14 Billion ↑ Strong Growth
Projected Market Size (2034) USD 6.43 Billion ↑ Sustained Expansion
Forecast CAGR (2026–2034) 8.29% ↑ High Growth
Dominant Treatment Type (2025) Hormonal Therapy ↑ Market Leader
Key Hormonal Therapy Estrogen Therapy ↑ Strong Adoption
Non-Hormonal Treatment Vaginal Moisturizers & Lubricants ↑ Increasing Adoption
Dominant Route of Administration Vaginal ↑ High Patient Preference
Primary Patient Group Postmenopausal Women ↑ Core Demand Base
Leading Distribution Channel Retail Pharmacies ↑ Strong Market Presence
Leading Region (2025) North America ↑ Market Leader
Fast-Growing Region Asia Pacific ↑ Rapid Growth

Strategic Investments in Atrophic Vaginitis Treatment Market:

In 2025, strategic investments in the Atrophic Vaginitis Treatment Market are focussed across the United States, Germany, France, United Kingdom, Japan, India, China, Canada, and Australia, driven by increasing investment in women’s health and menopause care.

Atrophic Vaginitis Treatment Country Investment
The U.S. and major European countries continue key investment hubs for novel hormonal, vaginal estrogen, DHEA, and non-hormonal therapies, while China, India, and Japan are gaining investment interest owing to aging female populations, expanding healthcare access, improving awareness, and growing demand for affordable and innovative menopause treatments.

Atrophic Vaginitis Treatment Market Dynamics:

Improved Healthcare Access and Treatment Availability:

Improved specialized women’s health services, healthcare infrastructure, digital healthcare platforms, pharmacy networks, and reimbursement coverage are growing patient access to atrophic vaginitis treatments. Wider availability of prescription and non-prescription therapies, together with convenient contained formulations, is supporting better treatment adherence, therapy continuity, and long-term patient outcomes.

Growing Postmenopausal Population and High Disease Burden:

The increasing number of postmenopausal and ageing women worldwide is growing the patient population requiring treatment for vaginal atrophy. The high prevalence of vaginal dryness, dyspareunia, irritation, and other GSM-related symptoms, combined with improving awareness and diagnosis, is consolidating demand for hormonal and non-hormonal therapies and driving growth of the atrophic vaginitis treatment market globally.

Atrophic Vaginitis Treatment Trends
Major Barriers to Global Atrophic Vaginitis Treatment Market Growth:

• Safety Concerns Related to Hormonal Therapies – Concerns regarding estrogen exposure and potential adverse effects can limit hormonal therapy adoption among certain patient groups.

• Low Disease Awareness & Underdiagnosis – Many women do not report vaginal atrophy symptoms, resulting in low diagnosis and treatment rates.

• High Treatment Costs and Reimbursement Limitations – Limited insurance coverage and high out-of-pocket expenses for certain branded therapies can restrict treatment accessibility.

• Limited Access to Specialized Women’s Healthcare – Shortages of gynecologists and menopause specialists, mainly in rural and developing regions, can reduce diagnosis and treatment penetration.

Atrophic Vaginitis Treatment Market Investment Opportunity Assessment 2025-2026

Investment Opportunity Opportunity Level Investment Focus Growth Potential
Non-Hormonal Therapeutics Very High 🔴 Vaginal DHEA, SERMs, hormone-free formulations, symptom-relief therapies Strong demand from patients seeking alternatives to estrogen-based treatments
Localized Vaginal Drug Delivery Very High 🔴 Vaginal tablets, rings, creams, inserts, sustained-release formulations High potential for improved efficacy, convenience, and patient adherence
Next-Generation Hormonal Therapies High 🟡 Low-dose estrogen, tissue-selective therapies, improved safety profiles Continued demand for effective localized hormone therapy
Emerging Market Commercialization Medium–High 🟡 China, India, Brazil, Southeast Asia, Middle East Large untreated patient population and improving women’s healthcare access
Strategic Licensing & Partnerships Medium–High 🟢 Co-development, licensing, commercialization, regional distribution agreements Supports faster market entry and broader geographic penetration

Atrophic Vaginitis Treatment Market Segment Insight 2025

By Treatment Type – Hormonal Therapy Dominates 2025

• Largest segment based on Treatment Type: Hormonal Therapy dominated the Global Atrophic Vaginitis Treatment Market in 2025.
• 2025 Market Share: 58.4%
• CAGR (2026–2034): 9.13%
• Broad adoption due to established clinical efficacy and physician familiarity
• Availability across estrogen creams, vaginal rings, and systemic hormone therapies
• Strong demand from the growing postmenopausal population

Atrophic Vaginitis Treatment Type Share
Based on Drug/Therapy Class – Estrogen Therapy Dominated 2025

• Largest segment in 2025: Estrogen Therapy dominated the Global Atrophic Vaginitis Treatment Market with a 42.15% share in 2025.
• Strong clinical use for moderate-to-severe vaginal atrophy/GSM symptoms
• Directly addresses the underlying estrogen deficiency
• Broad availability through creams, tablets/inserts, and vaginal rings
• Established physician familiarity and long-term treatment use

Atrophic Vaginitis Treatment Market by drug class

Atrophic Vaginitis Treatment Market Regional Analysis 2025-2034

North America: Dominant Region
• Nearly 38.2% global atrophic vaginitis treatment market share in 2025
• The U.S. dominates regional treatment demand
• High diagnosis and awareness of GSM and menopausal health
• Strong adoption of vaginal estrogen, SERMs, DHEA, and non-hormonal therapies
• Well-established insurance coverage, gynecology networks, and retail pharmacy infrastructure
• 2025 clinical guidance supports local low-dose vaginal estrogen as an important GSM treatment option.

Atrophic Vaginitis Treatment Market by Region

Europe: Established Treatment Market
• Germany, France, UK, and Italy are major atrophic vaginitis treatment markets
• Aging female population supports sustained treatment demand
• Strong public healthcare and reimbursement systems
• Increasing focus on low-dose estrogen and non-hormonal alternatives
• Advanced pharmaceutical R&D and menopause-care awareness support adoption.

Asia Pacific: High-Growth Opportunity
• Asia pacific expected to grow highest CAGR of 10.12% over 2026-2034.
• China, India, Japan, and South Korea are key markets
• Large and growing postmenopausal female population
• Improving awareness of menopause and vaginal health
• Growing healthcare expenditure and access to women's healthcare
• China is expected at 9.3% CAGR during 2026–2034, highlighting the region's growth potential.

Country-Wise Atrophic Vaginitis Treatment Market Position and Growth Opportunities, 2025:

Country Market Position Key Demand Drivers Major Growth Opportunities
United States Global Leader Strong prescription therapy adoption, High treatment penetration, advanced healthcare access Non-hormonal therapies, digital menopause care, localized delivery,
Germany European Leader Aging female population, established menopause care, high healthcare spending, Digital health, Low-dose estrogen, innovative formulations,
China High-Growth Market Large aging population, rising healthcare spending, improving awareness Localized therapies, domestic drug development, wider treatment access
Japan Mature Aging Market Advanced healthcare system, large postmenopausal population, Non-hormonal and localized therapies, patient education
United Kingdom Established Market Treatment accessibility, Strong menopause awareness, healthcare coverage, Digital women’s health, Vaginal therapies, non-hormonal alternatives

Atrophic Vaginitis Treatment Market Competitive Landscape

The Atrophic Vaginitis Treatment Market is characterized by a mix of world-wide pharmaceutical companies, women’s health specialists, and generic drug manufacturers competing over localized low-dose formulations, estrogen therapies, vaginal DHEA, SERMs, non-hormonal treatments, and improved vaginal drug-delivery systems. Competition is progressively focused on clinical efficacy, patient convenience, safety, affordability, and broader access to menopause care.

Leading companies with Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Duchesnay, Mayne Pharma/TherapeuticsMD, Bayer AG, Amneal Pharmaceuticals, and Theramex are strengthening their positions over strategic licensing, product innovation, generic competition, commercialization partnerships, and geographic atrophic vaginitis treatment market penetration. Established therapies like Premarin Vaginal Cream, Vagifem, Imvexxy, Osphena, Estring, and Intrarosa continue to shape competition, whereas emerging localized and non-hormonal therapies create opportunities for product differentiation.

Atrophic Vaginitis Treatment Companies

Atrophic Vaginitis Treatment Market Recent Developments

Year Development Area Key Development Impact
2025 Clinical Guidelines AUA/SUFU/AUGS released its 2025 GSM guideline, recommending local low-dose vaginal estrogen as an option for vaginal dryness, irritation, and dyspareunia. Strengthens clinical acceptance of localized estrogen therapy
2025 Regulatory / Hormone Therapy The U.S. FDA initiated changes to menopausal hormone therapy labeling, including proposed removal of several boxed-warning statements and more focused safety information for local vaginal estrogen products. Could improve physician and patient confidence in hormone-based treatments

What Competitors are Doing Right Now in Trophic Vaginitis Treatment Market

• Portfolio Strengthening- Competitors are consolidation vaginal estrogen, SERM, DHEA, and non-hormonal treatment portfolios.
• Product Innovation- Key Players are focusing on localized, low-dose, and patient-friendly drug delivery systems.
• Strategic Partnerships- Foremost players are partnerships, pursuing licensing, and geographic commercialization to increase Trophic Vaginitis Treatment Market penetration.

Atrophic Vaginitis Treatment Market Scope: Inquire before buying

Atrophic Vaginitis Treatment Market
Report Coverage Details
Base Year: 2025 Forecast Period: 2026-2034
Historical Data: 2020 to 2025 Market Size in 2025: USD 3.14 Bn.
Forecast Period 2026 to 2034 CAGR: 8.29% Market Size in 2034: USD 6.43 Bn.
Segments Covered: by Treatment Type Hormonal Therapy
Non-Hormonal Therapy
Other Therapies
by Drug/Therapy Class Estrogen Therapy
Selective Estrogen Receptor Modulators (SERMs)
Vaginal DHEA (Prasterone)
Vaginal Moisturizers
Vaginal Lubricants
Others
by Route of Administration Vaginal
Oral
Transdermal
Others
by Dosage Form Creams
Tablets & Inserts
Vaginal Rings
Gels
Suppositories/Ovules
Others
by Patient Type Natural Postmenopausal Women
Surgically Induced Menopause Patients
Treatment-Induced Menopause Patients
Others
by Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Atrophic Vaginitis Treatment Market by Region

North America (United States, Canada and Mexico)
Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam and the Rest of the Asia Pacific)
Middle East and Africa (MEA) (South Africa, GCC, Nigeria and the Rest of MEA)
South America (Brazil, Argentina, Colombia, Chile and the Rest of South America)

Global Atrophic Vaginitis Treatment Market Key Players

North America
1. Pfizer Inc.
2. TherapeuticsMD, Inc.
3. Duchesnay Inc.
4. AbbVie Inc.
5. Amneal Pharmaceuticals, Inc.
6. Viatris Inc.
7. Endoceutics, Inc.
8. Ascend Therapeutics, Inc.
9. Noven Pharmaceuticals, Inc.
10. Padagis LLC
11. Exeltis USA, Inc.
12. Prasco Laboratories

Europe
13. Novo Nordisk A/S
14. Theramex
15. Bayer AG
16. Gedeon Richter Plc
17. Sandoz Group AG
18. Ferring Pharmaceuticals
19. Hikma Pharmaceuticals PLC
20. Organon & Co.

Asia Pacific
21. Shionogi & Co., Ltd.
22. Teva Pharmaceutical Industries Ltd.*
23. Lupin Limited
24. Glenmark Pharmaceuticals Ltd.
25. Aurobindo Pharma Limited
26. Dr. Reddy's Laboratories Ltd.
27. Zydus Lifesciences Limited

Rest of World (RoW)
28. Adcock Ingram Holdings Ltd.
29. Aspen Pharmacare Holdings Limited
30. Eurofarma Laboratórios S.A.

Table of Contents

1. Atrophic Vaginitis Treatment Market Introduction 1.1. Study Assumptions and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Atrophic Vaginitis Treatment Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Key Players Benchmarking 2.2.1. Company Name 2.2.2. Headquarter 2.2.3. Product Segment 2.2.4. End-User Segment 2.2.5. Revenue Details in 2025 2.2.6. Market Share (%) 2.2.7. Profit Margin (%) 2.2.8. Return on Investment (%) 2.2.9. Technological Capabilities 2.2.10. Geographical Presence 2.3. Market Structure 2.3.1. Market Leaders 2.3.2. Market Followers 2.3.3. Emerging Players 2.4. Mergers and Acquisitions Details 3. Atrophic Vaginitis Treatment Market: Dynamics 3.1. Atrophic Vaginitis Treatment Market Trends 3.2. Atrophic Vaginitis Treatment Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.2.4. Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.5. Regulatory Landscape by Region 3.6. Key Opinion Leader Analysis for the Global Industry 3.7. Analysis of Government Schemes and Initiatives for Industry 4. Patient Treatment Journey & Therapy Switching Analysis 2026-2034 4.1. Symptom Onset-to-Diagnosis Patient Journey 4.2. Diagnosis-to-Treatment Conversion Analysis 4.3. First-Line Therapy Selection Patterns 4.4. Hormonal vs. Non-Hormonal Therapy Switching 4.5. Treatment Adherence, Persistence & Discontinuation 4.6. Key Switching Drivers: Efficacy, Safety, Cost & Convenience 5. Hormonal vs. Non-Hormonal Therapy Adoption Assessment 5.1. Therapy Adoption Rate by Treatment Type 5.2. Patient Preference and Treatment Selection 5.3. Physician Prescribing Patterns 5.4. Hormonal-to-Non-Hormonal Therapy Switching 5.5. Safety and Contraindication Impact on Adoption 5.6. Country-Level Therapy Adoption Trends, 2026–2034 6. Vaginal Estrogen Prescription & Utilization Analysis 6.1. Vaginal Estrogen Prescription Volume 6.2. Utilization by Formulation Type 6.3. New vs. Repeat Prescription Trends 6.4. Treatment Duration and Refill Patterns 6.5. Branded vs. Generic Utilization 6.6. Country-Level Prescription Trends 7. GSM Diagnosis-to-Treatment Conversion Analysis 7.1. Symptomatic vs. Diagnosed Patient Population 7.2. GSM Diagnosis Rate 7.3. Diagnosis-to-Treatment Conversion Rate 7.4. Treatment Initiation by Therapy Type 7.5. Key Barriers to Treatment Initiation 7.6. Country-Level Diagnosis and Treatment Gap, 2026–2034 8. Patent Expiry, Generic Entry & Loss-of-Exclusivity Analysis 8.1. Key Patent Expiry Timeline by Product 8.2. Loss-of-Exclusivity Risk Assessment 8.3. Generic Entry and Launch Pipeline 8.4. Brand Revenue Exposure to Generic Competition 8.5. Price Erosion Following Generic Entry 8.6. Country-Level Patent and Exclusivity Landscape 9. Menopause Clinic & Digital Health Treatment Pathway Analysis 9.1. Patient Access Through Menopause Clinics 9.2. Teleconsultation and Digital Diagnosis Pathways 9.3. E-Prescription and Online Pharmacy Integration 9.4. Digital Follow-up and Treatment Monitoring 9.5. Referral Pathways Between Primary Care and Specialists 9.6. Country-Level Adoption of Digital Menopause Care 10. Physician Prescribing Behavior & Therapy Preference Analysis 10.1. First-Line Therapy Preference by Physician Type 10.2. Hormonal vs. Non-Hormonal Prescribing Patterns 10.3. Therapy Selection by Symptom Severity 10.4. Influence of Safety, Efficacy and Contraindications 10.5. Brand vs. Generic Prescribing Preference 10.6. Country-Level Physician Treatment Preferences 11. Customer / Buyer-Level Demand Assessment 11.1. Demand by Patient and Buyer Type 11.2. Prescription vs. OTC Purchasing Patterns 11.3. Therapy Preference by Patient Group 11.4. Treatment Accessibility and Affordability 11.5. Buyer Willingness-to-Pay Assessment 11.6. Country-Level Demand and Unmet Need 12. Pricing Strategy, Cost Structure, Profitability, and Margin Optimization Assessment 12.1. Therapy-Level Pricing Benchmarking 12.2. Branded vs. Generic Price Comparison 12.3. Manufacturing and Commercialization Cost Structure 12.4. Gross Margin and Profitability Benchmarking 12.5. Reimbursement and Patient Out-of-Pocket Costs 12.6. Price and Margin Optimization Opportunities 13. Manufacturing Technology & Process Benchmarking 13.1. API and Formulation Manufacturing Processes 13.2. Vaginal Cream, Tablet, Ring & Insert Manufacturing 13.3. Hormonal vs. Non-Hormonal Production Benchmarking 13.4. Manufacturing Cost and Process Efficiency 13.5. Quality Control and Regulatory Compliance 13.6. Technology and Capacity Benchmarking by Manufacturer, 2026–2034 14. Treatment Persistence, Adherence & Discontinuation Analysis 14.1. Treatment Persistence by Therapy Type 14.2. Patient Adherence and Refill Patterns 14.3. Treatment Duration and Continuation Rates 14.4. Discontinuation Rate by Therapy 14.5. Key Discontinuation Drivers: Safety, Efficacy, Cost & Convenience 14.6. Therapy Switching Following Discontinuation 15. Regulatory Framework, Trade Policies, Product Standards, and Environmental Compliance Assessment 15.1. Drug Approval & Marketing Authorization Requirements 15.2. Clinical Trial, Safety & Efficacy Regulations 15.3. Hormonal and Non-Hormonal Therapy Regulatory Requirements 15.4. Product Labeling, Packaging & Pharmacovigilance Standards 15.5. Import–Export Regulations, Tariffs & Market Access Requirements 15.6. Pharmaceutical Manufacturing, GMP & Environmental Compliance Standards 16. Country-Level Treatment Penetration & Unmet Need Mapping 16.1. Treated vs. Untreated Patient Population 2025-26 16.2. Treatment Penetration Rate by Country 16.3. Diagnosis and Treatment Access Gap 16.4. Hormonal vs. Non-Hormonal Therapy Penetration 16.5. Patient Affordability and Accessibility Barriers 16.6. Country-Level Unmet Treatment Opportunity 17. Competitor Brand Positioning & Prescription Share Analysis 17.1. Leading Brand Prescription Share 2025-26 17.2. Brand Positioning by Therapy Class 17.3. Prescription Volume and Growth Trends 17.4. Physician Brand Preference 17.5. Brand Switching and Patient Retention 17.6. Competitor Performance by Country 18. Atrophic Vaginitis Treatment Market Entry Strategy & Target Country Prioritization 18.1. Country Attractiveness and Market Potential 18.2. Patient Population and Treatment Penetration 18.3. Regulatory and Reimbursement Attractiveness 18.4. Competitive Intensity and Entry Barriers 18.5. Pricing and Commercialization Strategy 18.6. Target Country Ranking and Entry Roadmap 19. Regional Demand Assessment, Consumer Spending Patterns, and Market Opportunity Analysis 19.1. Regional Treatment Demand and Growth 19.2. Patient Healthcare Spending Patterns 19.3. Prescription and OTC Spending Assessment 19.4. Treatment Affordability and Willingness-to-Pay 19.5. Regional Treatment Penetration and Access 19.6. High-Growth Market Opportunity Identification 20. Branded vs. Generic Therapy Competition Analysis 2026-2034 20.1. Branded vs. Generic Market Share 20.2. Price and Prescription Volume Comparison 20.3. Generic Substitution and Adoption Rate 20.4. Patent Expiry and Generic Entry Impact 20.5. Physician and Patient Brand Preference 20.6. Price Erosion and Competitive Pressure 21. White-Space Opportunity Mapping for Next-Generation GSM Therapies 21.1. Unmet Clinical Need Identification 21.2. Non-Hormonal Therapy Opportunity Mapping 21.3. Novel Drug Delivery Technology Opportunities 21.4. Underserved Patient Population Assessment 21.5. Pipeline and Competitive Gap Analysis 21.6. High-Potential Therapy & Innovation Opportunities 22. Investment Landscape and Emerging Business Potential Assessment 22.1. Investment Trends in Women’s Health & GSM Therapies 22.2. Investment by Therapy Type and Technology 22.3. Pharmaceutical R&D and Pipeline Investment 22.4. M&A, Licensing and Strategic Partnership Activity 22.5. Emerging Business Models and Commercial Opportunities 22.6. Country-Level Investment Hotspots and Future Potential 23. Global Atrophic Vaginitis Treatment Market Size and Forecast by Segmentation (by Value in USD Billion) (2025-2034) 23.1. Atrophic Vaginitis Treatment Market Size and Forecast, By Treatment Type (2025-2034) 23.1.1. Hormonal Therapy 23.1.2. Non-Hormonal Therapy 23.1.3. Other Therapies 23.2. Atrophic Vaginitis Treatment Market Size and Forecast, By Drug/Therapy Class (2025-2034) 23.2.1. Estrogen Therapy 23.2.2. Selective Estrogen Receptor Modulators (SERMs) 23.2.3. Vaginal DHEA (Prasterone) 23.2.4. Vaginal Moisturizers 23.2.5. Vaginal Lubricants 23.2.6. Others 23.3. Atrophic Vaginitis Treatment Market Size and Forecast, By Route of Administration (2025-2034) 23.3.1. Vaginal 23.3.2. Oral 23.3.3. Transdermal 23.3.4. Others 23.4. Atrophic Vaginitis Treatment Market Size and Forecast, By Dosage Form (2025-2034) 23.4.1. Creams 23.4.2. Tablets & Inserts 23.4.3. Vaginal Rings 23.4.4. Gels 23.4.5. Suppositories/Ovules 23.4.6. Others 23.5. Atrophic Vaginitis Treatment Market Size and Forecast, By Patient Type (2025-2034) 23.5.1. Natural Postmenopausal Women 23.5.2. Surgically Induced Menopause Patients 23.5.3. Treatment-Induced Menopause Patients 23.5.4. Others 23.6. Atrophic Vaginitis Treatment Market Size and Forecast, By Distribution Channel (2025-2034) 23.6.1. Hospital Pharmacies 23.6.2. Retail Pharmacies 23.6.3. Online Pharmacies 23.7. Atrophic Vaginitis Treatment Market Size and Forecast, By Region (2025-2034) 23.7.1. North America 23.7.1.1. United States 23.7.1.2. Canada 23.7.1.3. Mexico 23.7.2. Europe 23.7.2.1. United Kingdom 23.7.2.2. France 23.7.2.3. Germany 23.7.2.4. Italy 23.7.2.5. Netherlands 23.7.2.6. Spain 23.7.2.7. Sweden 23.7.2.8. Russia 23.7.2.9. Bahrain 23.7.2.10. Norway 23.7.2.11. Rest of Europe 23.7.3. Asia Pacific 23.7.3.1. China 23.7.3.2. South Korea 23.7.3.3. India 23.7.3.4. Japan 23.7.3.5. Australia 23.7.3.6. Indonesia 23.7.3.7. Philippines 23.7.3.8. Bangladesh 23.7.3.9. Malaysia 23.7.3.10. Vietnam 23.7.3.11. Thailand 23.7.3.12. Rest of Asia Pacific 23.7.4. Middle East and Africa 23.7.4.1. South Africa 23.7.4.2. Saudi Arabia 23.7.4.3. United Arab Emirates 23.7.4.4. Kuwait 23.7.4.5. Turkey 23.7.4.6. Egypt 23.7.4.7. Nigeria 23.7.4.8. Rest of Middle East & Africa 23.7.5. South America 23.7.6. Brazil 23.7.7. Argentina 23.7.8. Chile 23.7.9. Colombia 23.7.10. Rest of South America 24. Company Profile: Key Players 24.1.1. Company Overview 24.1.2. Business Portfolio 24.1.3. Financial Overview 24.1.4. SWOT Analysis 24.1.5. Strategic Analysis 24.1.6. Recent Development North America 24.1. Pfizer Inc. 24.2. TherapeuticsMD, Inc. 24.3. Duchesnay Inc. 24.4. AbbVie Inc. 24.5. Amneal Pharmaceuticals, Inc. 24.6. Viatris Inc. 24.7. Endoceutics, Inc. 24.8. Ascend Therapeutics, Inc. 24.9. Noven Pharmaceuticals, Inc. 24.10. Padagis LLC 24.11. Exeltis USA, Inc. 24.12. Prasco Laboratories Others Europe 24.13. Novo Nordisk A/S 24.14. Theramex 24.15. Bayer AG 24.16. Gedeon Richter Plc 24.17. Sandoz Group AG 24.18. Ferring Pharmaceuticals 24.19. Hikma Pharmaceuticals PLC 24.20. Organon & Co. Others Asia Pacific 24.21. Shionogi & Co., Ltd. 24.22. Teva Pharmaceutical Industries Ltd.* 24.23. Lupin Limited 24.24. Glenmark Pharmaceuticals Ltd. 24.25. Aurobindo Pharma Limited 24.26. Dr. Reddy's Laboratories Ltd. 24.27. Zydus Lifesciences Limited Others Rest of World (RoW) 24.28. Adcock Ingram Holdings Ltd. 24.29. Aspen Pharmacare Holdings Limited 24.30. Eurofarma Laboratórios S.A. Others 25. Key Findings 26. Analyst Recommendations 27. Atrophic Vaginitis Treatment Market: Research Methodology

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample